1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

GLOBAL CHOLESTEROL-LOWERING DRUGS MARKET 2017-2027

  • August 2017
  • 181 pages
  • Visiongain
Report ID: 5132830

Summary

Table of Contents

Please note: The license is valid for 12 months from the date the report is sent.


Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs

Report Details
The global cholesterol-lowering drugs market is expected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is estimated at $19.2bn in 2017. In the Statins and Fixed-Dose Combinations segment, Crestor was on the lead in 2016 and held a share of 26.7%.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 181-page report you will receive 89 tables and 107 figures – all unavailable elsewhere.

The 181-page report provides clear detailed insight into the global cholesterol-lowering drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
• Global Cholesterol-Lowering Drugs market forecasts from 2017-2027

This report also breaks down the revenue forecast from 2017-2027 for the global cholesterol-lowering drugs market by its main segments:
• Statins and Fixed-Dose Combinations
• Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates
• PCSK9 Inhibitors
• Novel Cholesterol-Lowering Drugs

This report provides revenue forecast from 2017-2027 for the leading drugs under the Statins and Fixed-Dose Combination segment:
• Crestor
• Lipitor
• Livalo
• Lescol/Lescol XL
• Zocor
• Vytorin
• Caduet
• Others

This report provides revenue forecast from 2017-2027 for the leading drugs under the Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates segment:
• Zetia
• Welchol
• Tricor
• Others

This report provides revenue forecast from 2017-2027 for the leading drugs under the PCSK9 Inhibitor segment:
• Praluent
• Repatha
• RN316
• Others

This report provides revenue forecast from 2017-2027 for the leading drugs under the novel cholesterol-lowering drugs segment:
• Juxtapid
• Kynamro
• MK-0859
• Others

This report provides individual revenue forecasts to 2027 for these regional and national markets:
• North America: the US, Canada, Mexico
• South America: Brazil, Argentina, Paraguay, Bolivia, Rest of South America
• Europe: Germany, France, the UK, Spain, Italy, Rest of Europe
• Asia-Pacific: Japan, China, India, Australia, Thailand, Rest of APAC
• RoW: Middle East, Africa, Other Countries

• Our study provides SWOT and Porter’s Five Forces analysis that influence the global cholesterol-lowering drugs market

Our study discusses the selected leading companies that are the major players in the cholesterol-lowering drugs market:
• AstraZeneca
• Merck & Co
• Pfizer
• Kowa Company
• Daiichi Sankyo
• AbbVie
• Novartis
• Sanofi
• Amgen
• Bristol-Myers Squibb (BMS)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Endothelial Dysfunction Global Clinical Trials Review, H2, 2017

  • $ 2500
  • Industry report
  • August 2017
  • by GlobalData

Endothelial Dysfunction Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Endothelial Dysfunction Global Clinical Trials Review, H2, 2017" provides an overview of ...

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2017

  • $ 2500
  • Industry report
  • August 2017
  • by GlobalData

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) ...

Dyslipidemia Global Clinical Trials Review, H2, 2017

  • $ 2500
  • Industry report
  • July 2017
  • by GlobalData

Dyslipidemia Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Dyslipidemia Global Clinical Trials Review, H2, 2017" provides an overview of Dyslipidemia clinical ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.